HTB homepage • Conference reports • Articles by subject • Subscribe November 2001 Contents Conference reports 8th European Conference on Clinical Aspects and Treatment of HIV-infection, Athens, 28-31 October 2001 HIV drug resistance can develop under HAART at low levels of viraemia Combinations of lopinavir/r and amprenavir in heavily treatment experienced patients Further reports of benefits of polylactic acid for facial lipoatrophy GigaHAART study shows benefit of treatment interruption prior to treatment with >7 drugs in highly treatment experienced patients Tenofovir DF 907 study The Max Cmin 1 trial: indinavir/ritonavir vs. saquinavir/ritonavir No significant drug interactions found between tenofovir DF and indinavir, lopinavir/r, lamivudine, or efavirenz Ritonavir corrects drug interaction between efavirenz and saquinavir Lopinavir/r effective in naive patients after three years of treatment Antiretrovirals Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV cohort study European CPMP gives positive opinion for European licensing of tenofovir DF EC approves abacavir for use by HIV-infected children Report on salvage therapy from the 39th annual meeting of the IDSA Side effects Preventable factors linked to indinavir-associated renal complications Nerve growth factor improves HIV-associated sensory neuropathy Lipodystrophy in HAART-treated patients may have multifactorial aetiology Coinfections and complications HIV infection may trigger neurologic disorder Hepatitis coinfection Daily injection more effective than thrice-weekly interferon alpha-2b for HCV/HIV Basic science and immunology HIV infects naive T cells leading to depletion Rapidly progressive HIV case highlights importance of specific immune response CCR5 density on T cells directly correlates with HIV disease progression Human herpes virus 6 prevents CCR5 tropic HIV from spreading in human tissue cultures Drug resistance Patients refractory to HIV treatment require close monitoring Other news South Africa hits out at pharmaceutical companies on AIDS drugs On the web The drug development pipeline When to start treatment tecommendations PDFs Volume 2 Number 9 November 2001 PDF HTB homepage • Conference reports • Articles by subject • Subscribe